FASEB
Federation of American Societies for Experimental Biology

David A. Boothman, PhD

FASEB Board of Directors

David A. Boothman is currently Professor of Pharmacology and Radiation Oncology, Associate Director for Translational Research, Simmons Comprehensive Cancer Center and the Robert B and Virginia Payne Professor of Oncology. He also holds the George and June Block Innovator Scholar through the American Association for Cancer Research/Pancreatic Cancer Action Network. Dr. Boothman also co-directs the Experimental Therapeutics Program, as well as the Cancer Targets and Nanomedicine Program within the Simmons Comprehensive Cancer Center.

Dr. Boothman received his PhD in Microbiology, Immunology and Biochemistry from the University of Miami. After a three-year post-doctoral fellowship in the Cell Growth and Regulation Division of the Dana-Farber Cancer Institute, Harvard Medical School with Dr. Arthur B. Pardee, Dr. Boothman was an Assistant Professor at the University of Michigan-Ann Arbor, a tenured Associate Professor at the University of Wisconsin-Madison, and full Professor at Case Western Reserve University. From 1999-2005, Dr. Boothman was Associate Director for Basic Research and co-Director of the Experimental Therapeutics Program, Case Western Reserve University Comprehensive Cancer Center. He also held the Case Western Reserve University Distinguished Investigator Award. In 2005, Dr. Boothman moved to UT Southwestern Medical Center to aid in development of infrastructure needed for standardized Phase I/II PharmacoDynamic (PD) laboratory correlates and aid in the development of the Simmons Cancer Center and subsequently the Simmons Comprehensive Cancer Center under the direction of Dr. James K.V. Willson. Dr. Boothman has over 20 years of experience in reviewing grant proposals for the NIH, DOE, DoD, NASA, FAMRI, AACR, states of Pennsylvania, Florida, New York and California, and governments of UK, Singapore, South Africa, Taiwan, Ireland, Qatar, The Netherlands and France.

Continued

FASEB
Federation of American Societies for Experimental Biology

Research in Dr. Boothman's laboratory is focused in three research areas: (i) DNA repair and links between RNA transcription termination, non-homologous end joining and genetic instability; (ii) PARP1 hyperactivation-induced programmed cell death and DNA repair inhibition; and (iii) TFGß1-induced gene expression and metabolic reprogramming during epithelial-to-mesenchymal transition (EMT) occurring during metastasis. The mission of all research in Dr. Boothman's lab is to move discoveries into the clinic to enhance cancer therapy using basic mechanistic data. His research on NQO1 bioactivatable drugs has led to three clinical trials, and his work on RNA termination factors has now allowed initiation of novel biomarkers that can be used to improve radio- and/or chemo-therapies.

January 2016